|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5412087A
(en)
|
1992-04-24 |
1995-05-02 |
Affymax Technologies N.V. |
Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
|
|
EP1179340A3
(en)
|
1994-09-30 |
2003-05-07 |
INEX Pharmaceutical Corp. |
Compositions for the introduction of polyanionic materials into cells
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
US5695937A
(en)
|
1995-09-12 |
1997-12-09 |
The Johns Hopkins University School Of Medicine |
Method for serial analysis of gene expression
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
WO2007086881A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
CA2742969A1
(en)
|
2008-11-07 |
2010-05-14 |
Fabrus Llc |
Anti-dll4 antibodies and uses thereof
|
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
|
US20110071208A1
(en)
|
2009-06-05 |
2011-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated dicer-substrate interfering rna
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
CA2769670C
(en)
|
2009-07-31 |
2018-10-02 |
Ethris Gmbh |
Rna with a combination of unmodified and modified nucleotides for protein expression
|
|
WO2012068627A1
(en)
|
2010-11-24 |
2012-05-31 |
The University Of Western Australia |
Peptides for the specific binding of rna targets
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
JP2018509387A
(ja)
|
2015-01-21 |
2018-04-05 |
フェーズアールエックス インコーポレイテッド |
細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
AU2016279077A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
US20190048340A1
(en)
|
2015-09-24 |
2019-02-14 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
|
CN116814590A
(zh)
|
2015-10-22 |
2023-09-29 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017083722A1
(en)
|
2015-11-11 |
2017-05-18 |
Greenberg Kenneth P |
Crispr compositions and methods of using the same for gene therapy
|
|
EP3390624A4
(en)
|
2015-12-18 |
2019-07-10 |
The Regents of The University of California |
Modified site-directed modifying polypeptides and methods of use thereof
|
|
US9896696B2
(en)
|
2016-02-15 |
2018-02-20 |
Benson Hill Biosystems, Inc. |
Compositions and methods for modifying genomes
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
EP3468612A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
AU2017280353B2
(en)
|
2016-06-24 |
2021-11-11 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
EP3500967A1
(en)
|
2016-08-17 |
2019-06-26 |
The Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
|
MX2019003674A
(es)
|
2016-09-30 |
2021-01-08 |
Univ California |
Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
|
|
US9982267B2
(en)
|
2016-10-12 |
2018-05-29 |
Feldan Bio Inc. |
Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
|
|
ES2928176T3
(es)
|
2017-01-10 |
2022-11-16 |
Christiana Care Gene Editing Inst Llc |
Métodos para mutagénesis dirigida al sitio in vitro mediante el uso de tecnologías de edición de genes
|
|
US20190367924A1
(en)
|
2017-02-17 |
2019-12-05 |
Temple University - Of The Commonwealth System Of Higher Education |
Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
|
|
SG11201906297QA
(en)
|
2017-03-24 |
2019-10-30 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
WO2018195555A1
(en)
|
2017-04-21 |
2018-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
|
|
US11578334B2
(en)
|
2017-10-25 |
2023-02-14 |
Monsanto Technology Llc |
Targeted endonuclease activity of the RNA-guided endonuclease CasX in eukaryotes
|
|
US10253365B1
(en)
|
2017-11-22 |
2019-04-09 |
The Regents Of The University Of California |
Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
|
|
US20200224160A1
(en)
|
2018-02-27 |
2020-07-16 |
Sorrento Therapeutics, Inc. |
Process for dna integration using rna-guided endonucleases
|
|
WO2019168950A1
(en)
|
2018-02-27 |
2019-09-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for treating angelman syndrome
|
|
WO2019213273A1
(en)
|
2018-05-01 |
2019-11-07 |
The Children's Medical Center Corporation |
Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9
|
|
EP3818167A4
(en)
|
2018-07-05 |
2022-04-13 |
The Regents of The University of California |
COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL
|
|
US20210284981A1
(en)
|
2018-07-24 |
2021-09-16 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
WO2020247883A2
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Deep mutational evolution of biomolecules
|
|
EP3980533A1
(en)
|
2019-06-07 |
2022-04-13 |
Scribe Therapeutics Inc. |
Engineered casx systems
|
|
US12454685B2
(en)
|
2019-07-08 |
2025-10-28 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
CN114340656B
(zh)
|
2019-08-02 |
2024-07-30 |
孟山都技术公司 |
使用huh内切核酸酶促进靶向基因组修饰的方法和组合物
|
|
WO2021050593A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of sod1
|
|
WO2021050601A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
WO2021084533A1
(en)
|
2019-10-28 |
2021-05-06 |
Targetgene Biotechnologies Ltd |
Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation
|
|
EP4069716A1
(en)
*
|
2019-12-06 |
2022-10-12 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
WO2021113763A1
(en)
|
2019-12-06 |
2021-06-10 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of rhodopsin
|
|
EP4069846A1
(en)
*
|
2019-12-07 |
2022-10-12 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of htt
|
|
IL294620A
(en)
|
2020-01-10 |
2022-09-01 |
Scribe Therapeutics Inc |
Compositions and methods for the targeting of pcsk9
|
|
AU2021237633A1
(en)
|
2020-03-18 |
2022-10-06 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of C9orf72
|
|
WO2022119957A1
(en)
|
2020-12-02 |
2022-06-09 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
KR20230128289A
(ko)
|
2020-12-03 |
2023-09-04 |
스크라이브 테라퓨틱스 인크. |
조작된 클래스 2 유형 v crispr 시스템
|
|
AU2021391783A1
(en)
|
2020-12-03 |
2023-06-22 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of bcl11a
|
|
WO2022125843A1
(en)
|
2020-12-09 |
2022-06-16 |
Scribe Therapeutics Inc. |
Aav vectors for gene editing
|
|
CA3212612A1
(en)
|
2021-03-26 |
2022-09-29 |
Brent E. STEAD |
Targeting oncogentic mutations with dual-cleaving endonuclease
|
|
WO2022261149A2
(en)
|
2021-06-09 |
2022-12-15 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
GB2625500B
(en)
|
2021-09-21 |
2026-04-01 |
Scribe Therapeutics Inc |
Engineered CasX repressor systems
|
|
EP4405490A2
(en)
|
2021-09-23 |
2024-07-31 |
Scribe Therapeutics Inc. |
Self-inactivating vectors for gene editing
|
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
GB2634837A
(en)
|
2022-06-07 |
2025-04-23 |
Scribe Therapeutics Inc |
Compositions and methods for the targeting of PCSK9
|
|
WO2023240157A2
(en)
|
2022-06-08 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of dmd
|
|
WO2024206676A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|